ZDHHC11B and non-small cell lung carcinoma: Expression of ZDHHC11B was positively associated with the sensitivity of savolitinib, a MET inhibitor, had been recently granted approval in China for treating metastatic NSCLC with MET exon 14-skipping alterations in patients who were unable to tolerate or failed from platinum-based chemotherapy [26].